Inclusion Criteria:

        Male and female subjects with CD 19+ B cell malignancies in patients with no available
        curative treatment options (such as autologous or allogeneic SCT) who have limited
        prognosis (several months to <2 year survival) with currently available therapies will be
        enrolled:

          1. Eligible diseases: CD 19+ leukemia or lymphoma

               1. ALL without curative options for therapy, including those not eligible for
                  allogeneic

                  SCT because of:

                    -  age

                    -  co-morbid disease

                    -  other contraindications to TBI-based conditioning (required for ALL SCT)

                    -  lack of suitable donor

                    -  prior SCT

                    -  Declines allo SCT (in CR3) as a therapeutic option after documented
                       discussion about the role of SCT with a BMT physician not part of the study
                       team. Note: Patient may be in any complete response, or patient may have
                       active disease but responding or stable after most recent therapy. The
                       intent is not to enroll patients with no degree of disease control, or
                       rapidly increasing disease burden between enrollment and cell infusion.

               2. Follicular lymphoma, previously identified as CD19+

                    -  At least 2 prior combination chemotherapy regimens (not including single
                       agent monoclonal antibody (Rituxan) therapy.

                    -  Stage III-IV disease.

                    -  Less than 1 year between last chemotherapy and progression (i.e. most recent
                       progression free interval <1 year).

                    -  Disease responding or stable after most recent therapy (chemotherapy, MoAb).

               3. CLL

                    -  At least 2 prior chemotherapy regimens (not including single agent
                       monoclonal antibody (Rituxan) therapy.

                    -  Less than 1 year between last chemotherapy and progression (i.e. most recent
                       progression free interval <1 year).

                    -  Not eligible or appropriate for conventional allogeneic SCT

                    -  Disease responding or stable after most recent therapy (chemotherapy, MoAb)

               4. Mantle cell lymphoma

                    -  Beyond 1st CR with relapsed or persistent disease and not eligible or
                       appropriate for conventional allogeneic or autologous SCT

                    -  Disease responding or stable after most recent therapy (chemotherapy, MoAb)

                    -  Relapsed after prior autologous SCT

               5. B-cell prolymphocytic leukemia (PLL) with relapsed or residual disease after at
                  least 1 prior therapy and not eligible for allogeneic SCT.

               6. Diffuse large cell lymphoma or other high-grade NHL, previously identified as
                  CD19+

                    -  Residual disease after primary therapy and not eligible for autologous SCT

                    -  Relapsed after prior autologous SCT

                    -  Beyond 1st CR with relapsed or persistent disease and not eligible or
                       appropriate for conventional allogeneic or autologous SCT

          2. Age 1 to 24 years. Patients ages 22-24 will only be enrolled if they are currently
             being treated at CHOP or another pediatric facility/oncologist

          3. Expected survival > 12 weeks

          4. Creatinine < 2.5 mg/dl and less than 2.5x normal for age

          5. ALT ≤ 5x normal

          6. Bilirubin <2.0 mg/dl

          7. Any relapse after prior SCT will make patient eligible regardless of other prior
             therapy

          8. Patients with relapsed disease after prior allogeneic SCT (myeloablative or
             non-myeloablative) will be eligible if they meet all other inclusion criteria and

               1. Have no active GVHD and require no immunosuppression

               2. Are more than 4 months from transplant

          9. For those patients who require leukapheresis for T cell collection (i.e. no previously
             collected product exists), adequate venous access for apheresis or eligible for
             appropriate catheter placement, and no other contraindications for leukapheresis

         10. Voluntary informed consent is given

         11. Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy
             (at infusion)

        Exclusion Criteria:

          1. Pregnant or lactating women. The safety of this therapy on unborn children is not
             known. Female study participants of reproductive potential must have a negative serum
             or urine pregnancy test performed within 48 hours before infusion

          2. Uncontrolled active infection

          3. Active hepatitis B or hepatitis C infection

          4. Concurrent use of systemic steroids at the time of cell infusion or cell collection,
             or a condition, in the treating physician's opinion, that is likely to require steroid
             therapy during collection or after infusion. Steroids for disease treatment at times
             other than cell collection or at the time of infusion are permitted. Use of inhaled
             steroids, or hydrocortisone for physiological replacement in patients with adrenal
             insufficiency are permitted as well

          5. Presence of grade 2-4 acute or extensive chronic GVHD

          6. Under treatment for GVHD

          7. Previous treatment with any gene therapy products

          8. Any uncontrolled active medical disorder that would preclude participation as
             outlined.

          9. HIV infection.

         10. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that
             might increase the risk of CNS toxicity